Covering the operations of the oil and gas industry
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
Sections
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
LNG
Energy Transition
Industry Statistics
Members Only
Special
Webcasts
White Papers
Podcast
Magazine
Surveys
Research
Events
Submit an Article
Iran war
Contact
About Us
Subscribe
Newsletters
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Affiliated Brands
OFFSHORE
ENERGYTECH
MICROGRID KNOWLEDGE
OGJ RESEARCH
Follow us on
http://www.facebook.com/ogjonline
https://www.linkedin.com/company/oil-&-gas-journal
http://twitter.com/ogjonline
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MaxCyte, Inc. - Common Stock
(NQ:
MXCT
)
0.8741
+0.0541 (+6.60%)
Streaming Delayed Price
Updated: 3:16 PM EDT, Apr 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MaxCyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript
↗
March 24, 2026
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
MaxCyte Inc (NASDAQ:MXCT) Reports Q4 2025 Revenue Miss and Cautious 2026 Outlook
↗
March 24, 2026
Via
Chartmill
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
March 24, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
March 23, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
February 24, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
February 23, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Planned CFO Transition in 2026
November 12, 2025
Company initiates search for successor
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 12, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
Insights into MaxCyte's Upcoming Earnings
↗
November 11, 2025
Via
Benzinga
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 05, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
October 08, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
October 06, 2025
MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapies
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
September 22, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
↗
August 11, 2025
Via
Benzinga
Thursday's session: top gainers and losers
↗
August 07, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 07, 2025
Via
Benzinga
Which stocks are moving on Thursday?
↗
August 07, 2025
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
Traders are paying attention to the gapping stocks in Thursday's session.
↗
August 07, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via
Chartmill
MaxCyte (MXCT) Q2 Revenue Drops 18%
↗
August 06, 2025
Via
The Motley Fool
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
August 06, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Platform License Agreement with Adicet Bio
August 04, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
July 31, 2025
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
July 09, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
June 11, 2025
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
May 07, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
